Treatment with glutathione precursor decreases cytokine activity

Journal of Parenteral and Enteral Nutrition

Volumn 23, Issue 1, 1999, Pages 1-6

  Pena, Luis R ^a   Hill, Daniell B ^a   McClain, Craig J ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; CYTOKINE; ENDOTOXIN; GLUTATHIONE; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; OXATHIZOLIDINE 4 CARBOXYLIC ACID; PRODRUG; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; KUPFFER CELL; LIVER CIRRHOSIS; LIVER DISEASE; MALE; MONOCYTE; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0032937658     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/014860719902300101     Document Type: Article

References (59)

1. Hill D, Shedlofsky S, McClain CJ, et al: Cytokines and liver disease. IN Cytokines in Health and Disease, 2nd ed. Remick D, Friedland J (eds). Marcel Dekker, New York, 1997, pp 401-425
2. McClain CJ, Hill DB, Schmidt J, et al: Cytokines and alcoholic liver disease. Semin Liver Dis 13:170-182, 1993
3. McClain CJ, Hill DB, Marsano L, et al: A Role for Cytokines in Alcoholic Hepatitis. Proceedings of the 1992 Conference on Alcohol, Drugs of Abuse, and Immunomodulators (AIDS), Vol 86, Pergamon Press, New York, 1993, pp 133-141
4. Tilg H, Wilmer A, Vogel W, et al: Serum levels of cytokines in chronic liver diseases. Gastroenterology 103:264-274, 1993
5. McClain CJ, Cohen DA: Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 9:349-351, 1989
6. Kroruts A, Stahnke L, McClain CJ, et al: Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 13:267-276, 1991
7. Felver ME, Mezey E, McGuire M, et al: Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 14:255-259, 1990
8. Deviere J, Content C, Denys C, et al: Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology 11:628-634, 1990
9. Bird GL, Sheron N, Goka AK, et al: Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 112:917-920, 1990
10. Deviere J, Content J, Denys C, et al: High interleukin-6 serum levels and increased production by leukocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokines production. Clin Exp Immunol 77:221-225, 1989
11. Sheron N, Bird G, Koskinas J, et al: Circulating and tissue levels of neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. Hepatology 18:41-46, 1993
12. Hill DB, Marsano LS, McClain CJ: Increased plasma interleukin-8 concentrations in alcoholic hepatitis. Hepatology 18:576-580, 1993
13. Hill DB, Schmidt J, Shedlofsky S, et al: In vitro tumor necrosis factor cytotoxicity in Hep G2 liver cells. Hepatology 21:1114-1119, 1995
14. Tiegs G, Wolter M, Wendel A: Tumor necrosis factor is terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol 38:627-631, 1989
15. Leist M, Wendel A: Tunicamycin potently inhibits tumor necrosis factor-induced hepatocyte apoptosis. Eur J Pharmacol 292: 201-204, 1995
16. Wang JF, Wendel A: Studies on the hepatotoxicity of galactosamine/endotoxin or galactosamine/TNF in the perfused mouse liver. Biochem Pharmacol 39:267-270, 1990
17. Czaja MJ, Flanders KC, Biempica L, et al: Expression of tumor necrosis factor-alpha and transforming growth factor-beta 1 in acute liver injury. Growth Factors 1:219-226, 1989
18. Leist M, Gantner F, Bohlinger I, et al: Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J Immunol 153:1778-1788, 1994
19. Mizoguchi Y, Tsutsui H, Miyajima K, et al: The protective effects of prostaglandin E1 in an experimental massive hepatic cell necrosis model. Hepatology 7:1184-1188, 1987
20. Arthur MJ: Corynebacterium parvum-elicited hepatic macrophages demonstrate enhanced respiratory burst activity compared with resident Kupffer cells in the rat. Gastroenterology 91:174-181, 1986
21. Smith S, Calzetta A, Bankowsky J, et al: Lipopolysaccharide-induced cytokine production and mortality in mice treated with corynebacterium parvum. J Leukocyte Biol 54:23-29, 1993
22. Honchel R, Marsano L, Cohen D, et al: Lead enhances lipopolysaccharide and tumor necrosis factor liver injury. J Lab Clin Med 117:202-208, 1991
23. Czaja MJ, Xu J, Ju Y, et al: Lipopolysaccharide-neutralizing antibody reduces hepatocyte injury from acute hepatotoxin administration. Hepatology 19:1282-1289, 1994
24. Chamulitrat W, Blazca M, Jordan S, et al: Tumor necrosis factor-alpha and nitric oxide production in endotoxin-primed rats administered carbon tetrachloride. Life Sci 57:2273-2280, 1995
25. Shedlofsky SI, Hoglen NC, Rodman LE, et al: 3,3′, 4,4′-Tetrabromobiphenyl sensitizes rats to the hepatotoxic effects of endotoxin by a mechanism that involves more than tumor necrosis factor. Hepatology 14:1201-1208, 1991
26. Colletti LM, Remick DG, Burtch GD, et al: Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 85:1936-1943, 1990
27. Sakr MF, McClain CJ, Gavaler JS, et al: FK 506 pretreatment is associated with reduced levels of tumor necrosis factor and interleukin-6 following hepatic ischemia/reperfusion. J Hepatol 17:301-307, 1993
28. Bhagwandeen SB, Apte M, Manwarring L: Endotoxin induced hepatic necrosis in rats on an alcohol diet. J Hepatol 152:47-53, 1987
29. Honchel R, Ray MB, Marsano L, et al: Tumor necrosis factor in alcohol enhanced endotoxin liver injury. Alcohol Clin Exp Res 16:665-669, 1992
30. Bemelmans MHA, Gouma DJ, Greve JW, et al: Cytokines tumor necrosis factor and interleukin-6 in experimental biliary obstruction in mice. Hepatology 15:1132-1136, 1992
31. Baggiolini M, Imboden P, Detmers P: Neutrophil activation and the effects of interleukin-8/neutrophil-activating peptide 1 (IL-8/NAP-1). IN Interleukin-8 (NAP-1) and Related Chemotactic Cytokines, Baggiolini M, Sorg C (eds). Karger, Basel, Switzerland, 1992, pp 1-17
32. Thornton AJ, Streiter RM, Lindley I, et al: Cytokine-induced gene expression of a neutrophil chemotactic factor/IL-8 in humans hepatocytes. J Immunul 144:2609-2613, 1990
33. Thornton AJ, Ham J, Kunkel SL: Kupffer cell-derived cytokines induce the synthesis of a leukocyte chemotactic peptide, interleukin-8, in human hepatoma and primary hepatocyte cultures. Hepatology 14:1112-1122, 1991
34. Hill DB, Marsano L, Cohen D, et al: Increased plasma interleukin-6 activity in alcoholic hepatitis. J Lab Clin Med 119:547-552, 1992
35. Schreck R, Albermann KAJ, Baeuerle PA: Nuclear factor kB: An oxidative stress-responsive transcription factor of eukaryotic cells (Review). Free Rad Res Commun 17:221-237, 1992
36. Tran-Thi T, Decker K, Baeuerle P: Differential activation of transcription factors NF-κB and AP-1 in rat liver macrophages. Hepatology 22:613-619, 1995
37. Sen CK, Packer L: Antioxidant and redox regulation of gene transcription. FASEB J 10:709-720, 1996
38. Beg A, Finco T, Nantermet P, et al: Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I-kappa-B-alpha: A mechanism for NFκB activation. Mol Cell Biol 13:3301-3310, 1993
39. Fox ES, Brower JS, Brower JS, et al: N-acetylcysteine and α-tocopherol reverse the inflammatory response in activated rat Kupffer cells. J Immunol 15:5418-5423, 1997
40. Hennig B, Toborek M, Joshi-Barve S, et al: Linoleic acid activates NFκB and induces NFκB dependent transcription in cultured endothelial cells. Am J Clin Nutr 63:322-328, 1996
41. Liu S-L, Esposti S, Yao T, et al: Vitamin E therapy of acute carbon tetrachloride-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. Hepatology 22:1474-1481, 1995
42. Meister A: New developments in glutathione metabolism and their potential application in therapy. Hepatology 4:739-742, 1984
43. Meister A: Glutathione metabolism and its selective modification. J Biol Chem 263:17205-17208, 1988
44. Roederer M, Staal FJT, Raju PA, et al: Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci USA 87:4884-4888. 1990
45. Staal FJT, Roederer M, Herzenberg LA, et al: Intracellular thils regulate activation of nuclear factor κB and transcription of human immunodeficiency virus. Proc Natl Acad Sci USA 87:9943-9947, 1990
46. Martensson J, Steinherz R, Jain A. et al: Glutathione ester prevents buthionine sulfoximine-induced cataracts and lens epithelial damage. Proc Natl Acad Sci USA 86:8727-8731, 1989
47. Olney JW, Ho O, Rhee V: Cytotoxic effects of acidic and sulphur containing amino acids on the infant mouse central nervous system. Exp Brain Res 14:61-76, 1971
48. Anderson M, Meister A: Intracellular delivery of cysteine. Methods Enzymol 143:313-325, 1987
49. Williamson JM, Meister A: Stimulation of hepatic glutathione formation by administration of L-2-oxothiazolidine-4-carboxylate, a 5-oxoprolinase substrate. Proc Natl Acad Sci USA 78:936-939, 1981
50. Chung TK, Funk MA, Baker DH: L-2-Oxothiazolidine-4-carboxylate as a cysteine precursor: Efficacy for growth and hepatic gluthione synthesis in chicks and rats. J Nutr 120:158-165, 1990
51. Roberts JC, Nagasawa HT, Zera RT, et al: Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)-and 2-(polyacetoxyalkyl) thiazolidine-4(R)-carboxylic acids. J Med Chem 30:1891-1896, 1987
52. Williamson JM, Boettcher B, Meister A: Intracellular cysteine delivery system that protects against toxicity by promoting glulathione synthesis. Proc Natl Acad Sci USA 79:6246-6249, 1982
53. Brodeur JL, Goyal R: Effect of a cysteine prodrug, L-2-oxothiazolidine-4-carboxylic acid, on the metabolism and toxicity of bromobenzene: An acute study. Can J Physiol Pharmacol 65:816-822, 1987
54. Lauterburg BH, Velez ME: Glutathione deficiency in alcoholics: Risk factor for paracetamol hepatotoxicity. Gut 29:1153-1157, 1988
55. Hirano T, Kaplowitz N, Tsukamoto H, et al: Hepatic mitochondrial glutathione depletion and progression of experimental alcoholic liver disease in rats. Hepatology 16:1423-1427, 1992
56. McSweegan E: TNF antibodies get new lease (Abstr). Nat Med 3:130, 1997
57. Elliott MJ, Maini RN, Feldmann M, et al: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) vs placebo in rheumatoid arthritis. Lancet 344:1105-1110, 1994
58. Van Dullemen HM, Van Deventer SJH, Hommes DW, et al: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129-135, 1995
59. Akerman PA, Cote P, Yang SQ, et al: Antibodies to tumor necrosis factor-α inhibit liver regeneration after partial hepatectomy. Am J Physiol 263:C579-585, 1992